drugset
drugset / Trial / NCT07651956

Remimazolam Versus Dexmedetomidine for Sedation During Neuraxial

NCT07651956 ↗

Phase 4 Not yet recruiting 150 enrolled Icahn School of Medicine at Mount Sinai
RandomizedParallel-groupDouble-blindTreatment

Summary

Patients presenting for a scheduled cesarean delivery who require a neuraxial anesthetic will be randomized to receive intravenous remimazolam or dexmedetomidine for procedural sedation during the placement of their spinal or epidural anesthesia.

Timeline

Start
2026-06
Primary completion
2028-05
Completion
2028-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.1 ug/kg Intravenous
Subject Remimazolam Small molecule 0.03 mg/kg Intravenous

Indications

anxiety